Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS

被引：0

作者：

Crusoe, Edvan De Queiroz ^{[1
,2
,3
]}

Leal, Joanna ^{[4
]}

Santos, Juliana Andrade ^{[5
,6
]}

de Melo Santos, Herbert Henrique ^{[7
]}

Santos, Allan de Souza ^{[7
]}

Lucas, Larissa Ferreira ^{[6
]}

Almeida, Alessandro de M. ^{[8
,9
]}

Chaves, Marcos ^{[10
]}

Dutra, Daniela Dourado ^{[5
]}

Hungria, Vania T. M. ^{[11
,12
]}

Salvino, Marco Aurelio ^{[2
,13
]}

Arruda, Maria da Gloria B. ^{[6
]}

机构：

[1] Univ Fed Bahia Hosp Univ, Rua Dra Doutro Vianna S-n, Salvador, BA, Brazil

[2] Hosp Univ Prof Edgard Santos Fed Univ Bahia HUPES, Salvador, BA, Brazil

[3] Clin CEHON Rede Dor Oncol, Hematol Dept Dor Oncol, Salvador, BA, Brazil

[4] Hematol Rede Dor Oncol, Hematol, Salvador, BA, Brazil

[5] Univ Fed Bahia, Salvador, BA, Brazil

[6] CLin CEHON Rede Dor Oncol, Hematol, Salvador, BA, Brazil

[7] Univ Fed Bahia, Immunol Mol & Cytometry Lab ICS, Salvador, BA, Brazil

[8] Univ Fed Bahia, Stem Cell Transplant Unit, Salvador, BA, Brazil

[9] Rede Dor Oncol, Hematol & Bone Marrow Unit, Salvador, BA, Brazil

[10] Fed Univ Bahia Hematol & Hemotheraphy, Salvador, BA, Brazil

[11] Santa Casa Med Sch, Hematol, Sao Paulo, Brazil

[12] Clin Sao Germano, Dept Hematol & Oncol, Sao Paulo, Brazil

[13] Rede Dor Oncol, Hematol & Bone Marrow Transplantat UNIT, Salvador, BA, Brazil

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-164866

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7699 / 7700

页数：2

共 50 条

[21] Stem Cell Collection with Daratumumab (DARA)Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies
Chhabra, Saurabh
Callander, Natalie S.
Costa, Luciano J.
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Bumma, Naresh
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Dholaria, Bhagirathbhai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Bartlett, J. Blake
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter M.
BLOOD, 2021, 138
[22] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sara A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Lutska, Yana
Bobba, Padma
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter M.
BLOOD, 2020, 136
[23] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sara A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Lutska, Yana
Bobba, Padma
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter M.
BLOOD, 2021, 138
[24] Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
Crusoe, Edvan De Queiroz
Higashi, Fabiana
Martinez, Gracia
Bittencourt, Rosane
Pinto Neto, Jorge Vaz
Sousa, Lais
Santucci, Rodrigo
Pessoa Magalhaes, Roberto Jose
Colli, Gilberto
Marques Nunes, Renata Ferreira
Ribeiro, Glaciano
Nicacio, Jandir
Zanella, Karla Richter
Kutner, Jose Mauro
Magalhaes, Andre
Leao, Danielle
Hallack Neto, Abrahao Elias
Braga, Walter
Souza, Emanuella G.
Guimaraes, Antonio Julio A. M.
Durigon, Giovanna Steffenello
Laks, Dani
Maiolino, Angelo
de Moraes Hungria, Vania Tietsche
HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2020, 42 (02) : 118 - 124
[25] Impact of Daratumumab (DARA) administration during transplant-eligible newly diagnosed Multiple Myeloma (TE NDMM) induction on stem cell (SC) mobilization count and post-transplant engraftment
Crusoe, Edvan
Almeida, Alessandro
Chaves, Marcos
Salvino, Marco
Nicanor, Jamile
Leal, JOanna
Santos, Herbert
Santos, Allan
Guimaraes, Victor
Dourado, Daniela
Lucas, Larissa
Santos, Mariane
Santos, Juliana
Arruda, Maria da Gloria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S131 - S131
[26] Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTD) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-Risk Patients in Cassiopeia
Sonneveld, Pieter
Attal, Michel
Perrot, Aurore
Hulin, Cyrille
Caillot, Denis
Facon, Thierry
Leleu, Xavier
Belhadj, Karim
Karlin, Lionel
Benboubker, Lotfi
Levin, Mark-David
Minnema, Monique C.
Westerman, Matthijs
Delforge, Michel
Zweegman, Sonja
Pei, Lixia
de Boer, Carla
Vanquickelberghe, Veronique
Kampfenkel, Tobias
Moreau, Philippe
BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 124 - 126
[27] A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
Figueiredo, Amarilis
Atkins, Harold
Mallick, Ranjeeta
Kekre, Natasha
Kew, Andrea
McCurdy, Arleigh
BLOOD, 2016, 128 (22)
[28] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin
Voorhees, Peter M.
Rodriguez, Cesar
Reeves, Brandi
Nathwani, Nitya
Costa, Luciano J.
Lutska, Yana
Bobba, Padma
Hoehn, Daniela
Pei, Huiling
Ukropec, Jon
Qi, Ming
Lin, Thomas S.
Richardson, Paul G.
BLOOD, 2020, 136
[29] Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) receiving daratumumab (DARA) plus bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study.
Hulin, Cyrille
Moreau, Philippe
Attal, Michel
Belhadj, Karim
Benboubker, Lotfi
Caillot, Denis
Facon, Thierry
Garderet, Laurent
Kuhnowski, Frederique
Stoppa, Anne-Marie
Kolb, Brigitte
Tiab, Mourad
Sonneveld, Pieter
Jie, Kon-Siong
Westerman, Matthijs
Pei, Lixia
Kampfenkel, Tobias
De Boer, Carla
Vermeulen, Jessica
van de Donk, Niels W. C. J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[30] Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA
Sonneveld, Pieter
Attal, Michel
Perrot, Aurore
Hulin, Cyrille
Caillot, Denis
Facon, Thierry
Leleu, Xavier
Belhadj-Merzoug, Karim
Karlin, Lionel
Benboubker, Lofti
Levin, Mark-David
Minnema, Monique
Westerman, Matthijs
Delforge, Michel
Zweegman, Sonja
Pei, Lixia
de Boer, Carla
Vanquickelberghe, Veronique
Kampfenkel, Tobias
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E2 - E3

← 1 2 3 4 5 →